• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Baxter shares dip despite Q1 earnings beat

April 25, 2019 By Fink Densford

Baxter

Shares in Baxter (NYSE:BAX) fell today despite the medical device maker beating expectations on Wall Street with its first quarter 2019 earnings results.

The Deerfield, Ill.-based company posted profits of $347 million, or 66¢ per share, on sales of approximately $2.63 billion for the three months ended March 31, seeing the bottom line shrink 10.8% while sales shrunk 1.7% compared with the same period during the previous year.

Adjusted to exclude one-time items, earnings per share were 76¢, well ahead of the 68¢ consensus on Wall Street where analysts expected to see sales of $2.61 billion, which the company topped.

“We are pleased with the solid start to 2019, establishing a foundation for accelerating performance over the course of the year. Our first quarter results reflect the value of our diversified portfolio, an increased emphasis on high-value innovation and an ongoing focus on operational excellence. We remain committed to executing on our strategy to deliver enhanced performance in 2019 and beyond,” chair & CEO José Almeida said in a press release.

Baxter raised its earnings outlook for 2019, expecting to post adjusted EPS of between $3.27 and $3.35 for the full year. For the coming second quarter, Baxter said it expects to post adjusted EPS of between 80¢ and 82¢ per diluted share.

Shares in Baxter are down 1.5% so far today, at $75.14 as of 9:50 a.m. EDT.

In February, Baxter said that it was cleared from a U.S. Dept. of Justice antitrust probe, launched in 2017, investigating companies that market intravenous saline solutions.

Filed Under: Business/Financial News, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Baxter

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS